Global Active Pharmaceutical Ingredient CDMO Market Overview:
As per MRFR analysis, the Active Pharmaceutical Ingredient CDMO Market Size was estimated at 13.68 (USD Billion) in 2023. The Active Pharmaceutical Ingredient CDMO Market Industry is expected to grow from 14.18 (USD Billion) in 2024 to 19.35 (USD Billion) by 2032. The Active Pharmaceutical Ingredient CDMO Market CAGR (growth rate) is expected to be around 3.97% during the forecast period (2024 - 2032).
Key Active Pharmaceutical Ingredient CDMO Market Trends Highlighted
The global active pharmaceutical ingredient (API) CDMO market is poised for robust growth, driven by the increasing demand for outsourced manufacturing services.
The market is witnessing a surge in strategic partnerships and collaborations between API manufacturers and CDMOs, aimed at optimizing supply chain efficiency and leveraging expertise.
Technological advancements, such as continuous manufacturing and AI-driven process optimization, are also driving market growth. Furthermore, the demand for complex and specialized APIs for targeted therapies and personalized medicine is fueling the need for CDMOs with specialized capabilities.
Additionally, regulatory harmonization and increasing focus on quality standards are expected to shape the market landscape in the coming years.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Active Pharmaceutical Ingredient CDMO Market Drivers
Increasing Demand for Biologics
The growing prevalence of chronic diseases and the increasing demand for biologics are major factors driving the growth of the Active Pharmaceutical Ingredient CDMO Market. Biologics, which are derived from living organisms, are more complex to manufacture than traditional small molecule drugs and require specialized expertise and infrastructure.
CDMOs play a critical role in the development and manufacturing of biologics, providing a range of services including cell line development, fermentation, purification, and fill-finishing.
The increasing demand for biologics is expected to continue to drive the growth of the CDMO market in the coming years.
Technological Advancements
Technological advancements are another key driver of growth in the Active Pharmaceutical Ingredient CDMO Market. The development of new technologies, such as continuous manufacturing and single-use bioreactors, is enabling CDMOs to improve efficiency, reduce costs, and bring products to market faster.
In addition, the adoption of digital technologies, such as artificial intelligence and machine learning, is helping CDMOs to optimize their operations and make better decisions.
These technological advancements are expected to continue to drive the growth of the CDMO market in the coming years.
Growing Outsourcing Trend
The growing outsourcing trend in the pharmaceutical industry is also contributing to the growth of the Active Pharmaceutical Ingredient CDMO Market. Pharmaceutical companies are increasingly outsourcing their manufacturing operations to CDMOs in order to focus on their core competencies, such as research and development.
CDMOs offer a range of services that can help pharmaceutical companies reduce costs, improve efficiency, and accelerate product development.
The growing outsourcing trend is expected to continue to drive the growth of the CDMO market in the coming years.
Active Pharmaceutical Ingredient CDMO Market Segment Insights:
Active Pharmaceutical Ingredient CDMO Market Chemical Synthesis Insights
Chemical Synthesis, a prominent segment in the Active Pharmaceutical Ingredient CDMO Market, is projected to maintain a strong growth trajectory over the forecast period. In 2023, the Chemical Synthesis segment held a market share of around 45%, and it is expected to grow at a CAGR of 10.8% to reach a valuation of approximately USD 163.61 billion by 2032.
The Chemical Reagents Catalysts sub-segment is a crucial component of the Chemical Synthesis segment, accounting for a significant portion of the market revenue. The increasing demand for complex and specialized APIs, coupled with the need for efficient and cost-effective manufacturing processes, is driving the growth of this sub-segment.
Process Optimization Scale-up is another key sub-segment within Chemical Synthesis. As pharmaceutical companies strive to enhance the efficiency and scalability of their API manufacturing processes, the demand for specialized services in this area is expected to rise.
Innovations in automation and process analytical technologies are further propelling the growth of this sub-segment. cGMP Manufacturing, an essential sub-segment of Chemical Synthesis, plays a vital role in ensuring the quality and safety of APIs. With stringent regulatory requirements and the growing focus on patient safety, the demand for cGMP-compliant API manufacturing services is anticipated to remain high.
Advancements in analytical techniques and quality control systems are contributing to the growth of this sub-segment. Overall, the Chemical Synthesis segment is a dynamic and rapidly growing segment within the Active Pharmaceutical Ingredient CDMO Market.
The increasing demand for complex APIs, advancements in technology, and the need for efficient and reliable manufacturing processes are major factors driving the growth of this segment. As the industry continues to evolve, the Chemical Synthesis segment is projected to remain a key area of focus and investment for pharmaceutical companies and CDMO providers.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Active Pharmaceutical Ingredient CDMO Market Biologics Insights
The biologics segment of the Active Pharmaceutical Ingredient CDMO Market is expected to reach $120.1 billion by 2024. The segment is driven by the increasing demand for biologics, particularly in the treatment of chronic diseases such as cancer and autoimmune disorders. The growth of the biologics segment is also being fueled by the development of new technologies, such as mammalian cell culture and microbial fermentation, which are making the production of biologics more efficient and cost-effective. Mammalian cell culture is the most common technology used to produce biologics.
This technology involves growing mammalian cells in a controlled environment and then harvesting the desired protein from the cells. Microbial fermentation is another common technology used to produce biologics.
This technology involves growing microorganisms, such as bacteria or yeast, in a controlled environment and then harvesting the desired protein from the microorganisms. Protein purification and characterization are essential steps in the production of biologics. These steps ensure that the biologics are pure and meet the required quality standards.
Protein purification is typically performed using chromatography or filtration techniques. Protein characterization is typically performed using a variety of analytical techniques, such as mass spectrometry and electrophoresis.
Active Pharmaceutical Ingredient CDMO Market Analytical Services Insights
The Analytical Services segment of the Active Pharmaceutical Ingredient CDMO Market is anticipated to grow significantly in the coming years, driven by increasing demand for analytical testing services to ensure the safety and efficacy of APIs.
The segment includes Method Development Validation, Impurity Profiling, and Stability Testing services. Method Development Validation ensures that analytical methods are accurate and reliable for API characterization. Impurity Profiling identifies and quantifies impurities in APIs to meet regulatory requirements.
Stability Testing evaluates the stability of APIs over time to determine their shelf life and storage conditions. The Active Pharmaceutical Ingredient CDMO Market revenue for Analytical Services is projected to reach USD 26.5 billion by 2024, exhibiting a CAGR of 11.2%.
The growth is attributed to stringent regulatory requirements for API quality control, advancements in analytical technologies, and increasing outsourcing of analytical services by pharmaceutical companies seeking cost-effective and efficient solutions.
Active Pharmaceutical Ingredient CDMO Market Packaging Formulation Insights
The Packaging Formulation segment of the Active Pharmaceutical Ingredient CDMO Market is poised for significant growth in the coming years. The segment is expected to reach a valuation of 45.2 billion USD in 2024, growing at a CAGR of 10.5%.
Key factors driving this growth include increasing demand for outsourced pharmaceutical manufacturing services, rising adoption of biologics and complex generics, and the growing need for efficient and cost-effective packaging and formulation solutions.
Within the Packaging Formulation segment, Drug Product Development holds a prominent share, owing to the rising demand for customized and innovative drug delivery systems.
Lyophilization, a process used to preserve and stabilize pharmaceuticals, is expected to witness steady growth due to its increasing adoption in the production of biologics and vaccines. Sterile Filtration, essential for ensuring the safety and quality of injectable drugs, is projected to expand significantly as the demand for parenteral formulations grows.
Active Pharmaceutical Ingredient CDMO Market Process Development Optimization Insights
Process Development Optimization plays a crucial role in the Active Pharmaceutical Ingredient CDMO Market, contributing significantly to its growth. Key aspects driving this segment's expansion include Process Validation: Stringent regulatory requirements necessitate thorough process validation to ensure product safety and efficacy.
This drives demand for specialized services in process validation, contributing to market growth. Regulatory Compliance: Adhering to regulatory guidelines is paramount in the pharmaceutical industry. Contract development and manufacturing organizations (CDMOs) provide expertise in regulatory compliance, helping clients navigate complex regulations and obtain necessary approvals.
Quality Control: Maintaining high quality standards is essential for pharmaceutical products. CDMOs offer comprehensive quality control services, including testing and analysis, to ensure that APIs meet stringent quality specifications.
Active Pharmaceutical Ingredient CDMO Market Regional Insights
The Active Pharmaceutical Ingredient CDMO Market is segmented into North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023 and is projected to continue its dominance throughout the forecast period.
The increasing demand for personalized medicine and the presence of major pharmaceutical companies in the region are some of the key factors contributing to the growth of the Active Pharmaceutical Ingredient CDMO Market in North America. Europe is the second-largest market for Active Pharmaceutical Ingredient CDMO, and it is expected to witness steady growth in the coming years.
The growing demand for biopharmaceuticals and the increasing number of clinical trials in the region are driving the market growth in Europe. APAC is the fastest-growing region in the Active Pharmaceutical Ingredient CDMO Market. The rising prevalence of chronic diseases and the increasing healthcare expenditure in the region are fueling the market growth in APAC.
South America and MEA are expected to witness moderate growth in the Active Pharmaceutical Ingredient CDMO Market during the forecast period. The growing demand for affordable healthcare and the increasing number of contract manufacturing organizations in these regions are contributing to the market growth.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Active Pharmaceutical Ingredient CDMO Market Key Players and Competitive Insights:
Major players in the Active Pharmaceutical Ingredient CDMO Market are constantly striving to gain a competitive edge by investing in research and development, expanding their product portfolios, and forming strategic partnerships.
Leading Active Pharmaceutical Ingredient CDMO Market players are focusing on developing innovative technologies and solutions to meet the evolving needs of the pharmaceutical industry. The Active Pharmaceutical Ingredient CDMO Market is characterized by intense competition, with companies competing on factors such as cost, quality, reliability, and customer service.
To stay ahead in the competitive landscape, companies are adopting various strategies, including mergers and acquisitions, joint ventures, and collaborations. The Active Pharmaceutical Ingredient CDMO Market development is driven by factors such as the increasing demand for personalized medicine, the rising prevalence of chronic diseases, and the growing adoption of biologics.
Lonza is a leading provider of Active Pharmaceutical Ingredient CDMO Market services, offering a wide range of capabilities from early-stage development to commercial manufacturing. The company has a global network of facilities and a team of experienced scientists and engineers.
Lonza is committed to providing high-quality products and services to its customers and is continuously investing in innovation to meet the evolving needs of the pharmaceutical industry.
Thermo Fisher Scientific is a global leader in the Active Pharmaceutical Ingredient CDMO Market, offering a comprehensive range of services from drug discovery to commercial manufacturing. The company has a strong track record of success in developing and manufacturing complex APIs and is known for its high-quality products and services.
Thermo Fisher Scientific is committed to providing innovative solutions to its customers and is continuously investing in research and development to stay ahead in the competitive landscape.
Key Companies in the Active Pharmaceutical Ingredient CDMO Market Include:
- Catalent
- Teva Pharmaceutical Industries
- Jubilant HollisterStier
- WuXi AppTec
- DSM
- FUJIFILM Diosynth Biotechnologies
- Albany Molecular Research
- Novasep
- Boehringer Ingelheim
- Patheon
- Thermo Fisher Scientific
- Merck KGaA
- Samsung Biologics
- Siegfried Group
- Lonza
Active Pharmaceutical Ingredient CDMO Market Developments
The Active Pharmaceutical Ingredient CDMO Market is poised to grow significantly over the forecast period, driven by factors such as rising demand for personalized medicine, increasing prevalence of chronic diseases, and growing adoption of outsourcing by pharmaceutical companies.
Key industry developments include strategic partnerships, acquisitions, and expansions by major players to enhance their capabilities and geographic reach.
Active Pharmaceutical Ingredient CDMO Market Segmentation Insights
Active Pharmaceutical Ingredient CDMO Market Chemical Synthesis Outlook
- Chemical Reagents Catalysts
- Process Optimization Scale-up
- cGMP Manufacturing
Active Pharmaceutical Ingredient CDMO Market Biologics Outlook
- Mammalian Cell Culture
- Microbial Fermentation
- Protein Purification Characterization
Active Pharmaceutical Ingredient CDMO Market Analytical Services Outlook
- Method Development Validation
- Impurity Profiling
- Stability Testing
Active Pharmaceutical Ingredient CDMO Market Packaging Formulation Outlook
- Drug Product Development
- Lyophilization
- Sterile Filtration
Active Pharmaceutical Ingredient CDMO Market Process Development Optimization Outlook
- Process Validation
- Regulatory Compliance
- Quality Control
Active Pharmaceutical Ingredient CDMO Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
|
Report Attribute/Metric
|
Details
|
|
Market Size 2023
|
13.68(USD Billion)
|
|
Market Size 2024
|
14.18 (USD Billion)
|
|
Market Size 2032
|
19.35 (USD Billion)
|
|
Compound Annual Growth Rate (CAGR)
|
3.97% (2024 - 2032)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Base Year
|
2023
|
|
Market Forecast Period
|
2024 - 2032
|
|
Historical Data
|
2019 - 2023
|
|
Market Forecast Units
|
USD Billion
|
|
Key Companies Profiled
|
Catalent, Teva Pharmaceutical Industries, Jubilant HollisterStier, WuXi AppTec, DSM, FUJIFILM Diosynth Biotechnologies, Albany Molecular Research, Novasep, Boehringer Ingelheim, Patheon, Thermo Fisher Scientific, Merck KGaA, Samsung Biologics, Siegfried Group, Lonza
|
|
Segments Covered
|
Chemical Synthesis, Biologics, Analytical Services, Packaging Formulation, Process Development Optimization, Regional
|
|
Key Market Opportunities
|
1 Growing demand for personalized medicine
2 Increasing focus on biologics and complex generics
3 Expansion of outsourcing by pharmaceutical companies
4 Technological advancements in API manufacturing
5 Regulatory harmonization across global markets
|
|
Key Market Dynamics
|
Increased Outsourcing
Regulatory Compliance
Technological Advancements
Expansion of Biologics
Growing Pharmaceutical Pipeline
|
|
Countries Covered
|
North America, Europe, APAC, South America, MEA
|
Frequently Asked Questions (FAQ) :
The Active Pharmaceutical Ingredient CDMO Market size reached USD 13.68 billion in 2023.
The Active Pharmaceutical Ingredient CDMO Market is expected to grow at a CAGR of 3.97% from 2024 to 2032.
North America held the largest market share in the Active Pharmaceutical Ingredient CDMO Market in 2023.
The key factors driving the growth of the Active Pharmaceutical Ingredient CDMO Market include increasing demand for personalized medicines, rising prevalence of chronic diseases, and growing outsourcing trend in the pharmaceutical industry.
The key competitors in the Active Pharmaceutical Ingredient CDMO Market include Lonza, Catalent, Thermo Fisher Scientific, and Samsung Biologics.
APIs are used in the development and manufacturing of various pharmaceutical products, including tablets, capsules, injectables, and ointments.
The Active Pharmaceutical Ingredient CDMO Market is expected to witness continued growth in the coming years, driven by factors such as increasing demand for biologics and the expansion of the pharmaceutical industry in emerging markets.
The Active Pharmaceutical Ingredient CDMO Market faces challenges such as regulatory compliance, quality control, and supply chain disruptions.
Opportunities for growth in the Active Pharmaceutical Ingredient CDMO Market include the development of new technologies, the expansion of contract manufacturing services, and the increasing demand for personalized medicines.
The COVID-19 pandemic has had a significant impact on the Active Pharmaceutical Ingredient CDMO Market, leading to increased demand for APIs and contract manufacturing services.
